缬沙坦分散片+硝苯地平控释片联合用药方案治疗原发性高血压病的临床研究

Clinical study on the combination of valsartan dispersible tablets and nifedipine controlled-release tablets in the treatment of essential hypertension

目的探究缬沙坦分散片+硝苯地平控释片联合用药方案治疗原发性高血压病的临床效果和安全性。方法 80例原发性高血压病患者,按照随机数字表法分为对照组(39例)和试验组(41例)。对照组采用硝苯地平控释片治疗,试验组采用缬沙坦分散片+硝苯地平控释片联合用药方案治疗。比较两组的临床疗效、治疗前后血清免疫球蛋白G(IgG)、补体C3水平及不良反应发生情况。结果试验组的总有效率为95.12%,显著高于对照组的79.49%,差异具有统计学意义(P<0.05)。治疗前,两组血清IgG、补体C3比较差异无统计学意义(P>0.05)。治疗后,两组血清IgG、补体C3均较治疗前降低,差异有统计学意义(P<0.05)。试验组治疗后血清IgG、补体C3分别为(10.65±2.86)g/L、(872.11±43.64)mg/L,均低于对照组的(15.11±2.32)g/L、(912.27±43.51)mg/L,差异均有统计学意义(P<0.05)。试验组不良反应发生率为4.88%,与对照组的2.56%比较差异无统计学意义(P>0.05)。结论针对原发性高血压病患者,采用缬沙坦分散片联合硝苯地平控释片治疗可降低血压,改善血清IgG、补体C3水平,更利于疾病恢复,且未增加不良反应发生率,值得临床借鉴。

Objective To investigate the clinical effect and safety of combination of valsartan dispersible tablets and nifedipine controlled-release tablets in the treatment of essential hypertension. Methods A total of 80 essential hypertension patients were divided into control group(39 cases) and experimental group(41 cases) by random number table method. The control group was treated by nifedipine controlled-release tablets, and the experimental group was treated by combination of valsartan dispersible tablets and nifedipine controlled-release tablets. The clinical efficacy, serum immunoglobulin G(IgG) and complement C3 levels before and after treatment and occurrence of adverse reactions was compared between the two groups. Results The total effective rate was 95.12% in the experimental group, which was significantly higher than 79.49% in the control group, and the difference was statistically significant(P<0.05). There was no statistically significant difference in serum IgG and complement C3 before treatment between the two groups(P>0.05). After treatment, the serum IgG and complement C3 in the two groups was lower than those before treatment, and their difference was statistically significant(P<0.05). After treatment, the serum IgG and complement C3 was(10.65±2.86) g/L and(872.11±43.64) mg/L respectively in the experimental group, which was lower than(15.11±2.32) g/L and(912.27±43.51) mg/L in the control group, and their difference was statistically significant(P<0.05). The incidence of adverse reactions was 4.88%, which had no statistically significant difference compared with 2.56% in the control group(P>0.05). Conclusion For essential hypertension, combination of valsartan dispersible tablets and nifedipine controlledrelease tablets can reduce blood pressure, improve the level of serum IgG and complement C3, which is more conducive to the recovery of the disease without increase of incidence of adverse reactions. It is worthy of clinical reference.